Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center




Neratinib HER Mutation Basket Study

Multiple Cancer Types

This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Bladder, Colon, Esophageal, Gastric/Gastroesophageal, Neuro-Oncology, Ovarian, Urologic, Uterine
II
Mayer, Ingrid
NCT01953926
VICCMD1403

Testing Platinum-based Chemotherapy after Surgery in Triple-Negative Breast Cancers

Breast

This phase III trial compares the effect of cisplatin or carboplatin (platinum based chemotherapy) to capecitabine after surgery for the treatment of residual triple-negative breast cancer. Chemotherapy drugs, such as cisplatin, carboplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. At present, upon completion of chemotherapy and surgery, the standard of care for patients with triple-negative breast cancer is observation. However, recent studies have shown that giving capecitabine after completion of chemotherapy and surgery is a better treatment than receiving no treatment and also that platinum-based chemotherapy after surgery could prevent residual triple-negative breast cancer from returning. This trial is being done to find out whether addition of a platinum agent after completion of surgery will provide a higher disease free survival benefit than capecitabine in treating patients with residual triple-negative breast cancer.
Breast
III
Mayer, Ingrid
NCT02445391
ECOGBREEA1131

Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Breast

This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor (locally recurrent), has spread to other places in the body (metastatic), or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
Breast
II
Mayer, Ingrid
NCT03125928
VICCBRE18179

Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Mayer, Ingrid
NCT03694249
VICCMD1854

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: